If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

Johnson & Johnson (JNJ) looks like it may need to take some Motrin to stave of the public-relations headache it's facing. Oh wait ... maybe that's not such a good idea. Motrin is the problem.

It turns out Johnson & Johnson learned about some problems with its Motrin formulas in November 2008. But instead of issuing a recall and letting the public know of the problem, Johnson & Johnson hired an outside contractor to go around and collect samples to see if the company should issue a full recall. Oops.

I want to buy something today. I haven't yet, but I really just want to get in there and get something. Here's what's stopping me:

Uncertainty. Yes, the dreaded unknown, the beast that is lurking around the corner, the one that might look an awful lot like an angry ursine monster. The way the market is falling, I get the feeling we could be in for a rough summer. There's no way of knowing, of course; stocks could return to bull-mode status tomorrow. Seriously, though, does it honestly feel that way? I'd be shocked if anyone could proffer such a sentiment with unwavering truthfulness.

The market continues to be very volatile and trending down. When the seas are this turbulent you want to be on the biggest ships and thus I continue my review of the super cap stocks. This time, I'm going to examine return-on-equity (ROE) and return on-invested-capital (ROIC).

I started with the 12 highest valued companies but remained with 10 after running them through several screens. Among those 10 super, caps the company that is producing the highest returns is Microsoft (MSFT).

It's a cliché but it rings so true: just show me the money! In the case of stocks that's profits and distributions, or dividends.

The super cap review, in which I examine large cap stocks through different valuation methods, started with the 12 stocks with the highest capitalization and through several stock screens has been trimmed to just 10 stocks.

It has been widely reported that dividends contribute as much as 40% of the market stock appreciation on long term holdings. All things being equal, a diversified basket of dividend paying stocks should outperform a similarly diversified portfolio that does not.

Over the years I have referred to "my pal Warren" (Warren Buffet) on many occasions. He has taught me a great deal. I have learned a few things from Sir John Templeton (RIP) as well. But when I think about the price-to-earnings-to-growth (PEG) ratios, it is Peter Lynch who stands tall.

Lynch has been retired for many years and has been generous enough to share some of his thoughts in a couple of worthy books: One Up on Wall Street and Beating the Street. I highly recommend these best sellers to anyone that wants to expand their knowledge of value investing or manage their own finances.

In my search for value investments among the top twelve stocks by capitalization -- the "super caps" -- I began by reviewing the price-to-earnings and price-to-sales ratios. Today we will move on to examine price-to-book (P/B) and price-to-cash flow (P/CF).

If you are one of the lucky ones that benefited from the market's long rise from the depths of Hades and are now looking to rotate into less volatile positions, or you still remain apprehensive and want to stake out a new position, some of these super caps may be just for you.